Sight Sciences (SGHT) Projected to Post Earnings on Wednesday

Sight Sciences (NASDAQ:SGHT) is expected to be issuing its quarterly earnings data after the market closes on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $18.98 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Sight Sciences Stock Up 0.4 %

SGHT stock opened at $2.65 on Monday. Sight Sciences has a 12 month low of $2.29 and a 12 month high of $8.45. The firm has a market cap of $134.50 million, a PE ratio of -2.60 and a beta of 2.52. The firm has a 50 day simple moving average of $3.01 and a 200 day simple moving average of $4.51. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74.

Insider Activity at Sight Sciences

In other news, CEO Paul Badawi sold 24,819 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $2.92, for a total transaction of $72,471.48. Following the completion of the sale, the chief executive officer now owns 5,676,331 shares of the company’s stock, valued at $16,574,886.52. This trade represents a 0.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 63,014 shares of company stock worth $197,295 in the last quarter. 28.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

SGHT has been the subject of several recent research reports. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research report on Tuesday, January 14th. Lake Street Capital dropped their price objective on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Wednesday, January 15th. Piper Sandler restated a “neutral” rating and issued a $5.50 price objective (down previously from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Morgan Stanley reduced their target price on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, November 11th. Finally, Citigroup reduced their price objective on shares of Sight Sciences from $5.80 to $4.60 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.68.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.